newsfilter
← Latest News
GlobeNewswire·

Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed